Targeted Therapies, Predispositions, and Survivorship in Pediatric Cancers

• 7870 Targeting the MYC-SUMO axis with TAK-981 reverses immune suppression and restores antigen presentation in osteosarcoma Bikesh Kumar Nirala, Jeffrey Ritzenthaler, Tajhal Patel, Taku Yamamichi, Ryo Tsukada, Lyazat Kurenbekova, Juan Dou, Heath Bradley, Atreyi Dasgupta, Jason T. Yustein
• 7871 · PDF Onvansertib-mediated PLK1 inhibition reduces cell viability in neuroblastoma cells Aileen A. Yasukochi, Susanna Kim, CARLA SAMPAIO, Peter E. Zage
• 7872 · PDF CDK7 inhibition mitigates AZD1775 resistance via chromatin reprogramming in MYC-MB Kiara Smart, Bethany Veo, Rajeev Vibhakar
• 7873 In vivo preclinical efficacy of a novel “payload-bearing” peptide LX-101 targeting IGF-1R in Ewing sarcoma Roberto Cardenas-Zuniga, Jiaqian Fan, Asmaa G. Ahmed, Marcus Thurm, Kien Ryan Cao, Clement Agyemang, Danh Truong, Joseph A. Ludwig
• 7874 Dose-response efficacy of cell adhesion molecule 1 (CADM1)-GGFG-Exatecan vs CADM1-PEG3-VC-Exatecan in preclinical osteosarcoma models Zhongting Zhang, Caterina Longo, Wendong Zhang, Yifei Wang, Yanhua Yi, Zhaohui Xu, Xin Zhou, Adil Bahadir, Michael Roth, Jonathan Gill, Richard Gorlick
• 7875 · PDF Eflornithine and venetoclax combination therapy: Targeting senescence to induce apoptosis in neuroblastoma Tarlan Arjmandi, Jeremy Hengst, Muhammad Younis, Meenakshi Shukla, Mohammad Haque, Katherine McClain, Jonathan Lerch, Thussenthan Walter-Angelo, Giselle Saulnier Sholler
• 7876 Melatonin protects against long-term doxorubicin-induced cardiotoxicity in a preclinical model of childhood cancer survivors Marisol Fernandez Ortiz, Logan Davis, Joseph Schell, Erik Marchant, Blake Rasmussen, David Gius, Gregory Aune
• 7877 Combination of AVA-NP-695 and DDRi demonstrates strong synergy resulting in potent anti-tumor activity in rare pediatric cancers Aditya Kulkarni, Borja Ruiz-Fernandez de Cordoba, Avijit Goswami, Sandeep Goyal, Kawaljit Singh, Princy Khurana, Alejandro Sweet-Cordero
• 7878 Disrupting the lipid-ETV6 axis: A therapeutic vulnerability in Ewing sarcoma Yuan Gao, Hang Zhao
• 7879 Opaganib in combination with oxaliplatin and doxorubicin as a novel salvage therapy for relapsed/refractory high-risk neuroblastoma Jeremy Hengst, Mohammad Haque, Muhammad Younis, Thussenthan Walter Angelo, Anna Bourne, Katherine McClain, Meenakshi Shukla, Jonathan Lerch, Tarlan Arjmandi, Eric Cochran, Lynn Maines, Charles D. Smith, Vladimir S. Spiegelman, Jacqueline M. Kraveka, Giselle L. Saulnier Sholler
• 7881 · PDF Hijacking the BRD4-NUT fusion oncoprotein to activate programmed cell death Kelly Wang, Yanlan Wang, Tian Qiu, Brendan G. Dwyer, Daryl Griffin, Geoffrey I. Shapiro, Chris A. French, Nathanael S. Gray, Gerald R. Crabtree
• 7883 Surface CADM1 (Cell Adhesion Molecule 1) abundance predicts payload delivery and in-vitro efficacy of CADM1-GGFG-Exatecan ADC in osteosarcoma, aiding optimal candidate selection Caterina Longo, Zhongting Zhang, Wendong Zhang, Yifei Wang, Adil Bahadir, Yi Yanhua, Zhaohui Xu, Xin Zhou, Michael Roth, Jonathan Gill, Richard Gorlick
• 7884 · PDF Germline genetic testing trends in pediatric cancer patients: A SEER registry analysis Claire Johns, Minxuan Huang, Rebecca Hodan, Molly McGuinness, Allison W. Kurian, Raya Saab
• 7885 Defining genome-wide cfDNA methylation landscapes in pediatric and adolescent and young adult (AYA) bone and soft-tissue sarcomas Lilli J. Greiner, Roman O. Kowalchuk, Jeff Szymanski, Pradeep S. Chauhan, Adam Amundson, Peter J. Schoettler, Wendy Allen-Rhoades, Stephanie F. Polites, Peter S. Rose, Kelly Bailey, Linda McAllister-Lucas, Anita Mahajan, Nadia Laack, Aadel Chaudhuri
• 7886 · PDF Therapy-related clonal hematopoiesis in pediatric cancer survivors Michael R. Kessler, Yash Pershad, Robert W. Corty, Eric T. Shinohara, Debra Friedman, Alexander G. Bick, Ben H. Park, Leo Y. Luo
• 7887 Associations between polygenic risk scores for immune dysregulation and Hodgkin lymphoma in childhood cancer survivors Ji Yun Tark, Sharon M. Castellino, Philip J. Lupo, Austin L. Brown
• 7888 · PDF Financial hardships and chronic medical conditions in adolescent and young adult cancer survivors Diego Del Toro Rivera, Qian Li, Anne Kirchhoff, Salene M. Jones, Candice A. M. Sauder, Ann M. Brunson, Charles P. Quensenberry, Lisa M. Moy, Renata Abrahao, Ted Wun, Hazel B. Nichols, Lawrence H. Kushi, Jessica Chubak, Erin E. Hahn, Theresa H. M. Keegan
• 7889 · PDF Integrating genetic predictors into breast cancer risk stratification among female survivors of childhood cancer Aparna Srinivasan, Jian Wang, Gavriel Matt, Lauren J. Mills, Yadav Sapkota, Zhaoming Wang, Tianzhong Yang, Joseph P. Neglia, Lucie M. Turcotte, Melissa M. Hudson, Kirsten K. Ness, Gregory T. Armstrong, Jinghui Zhang, Leslie L. Robison, Xin Zhou, Yutaka Yasui, Cindy Im
• 7890 · PDF Insights into chemotherapy-related cognitive impairment in childhood acute myeloid leukemia survivors Joel Costoya, Carolyn Cabrera, Joaquin J. Jimenez
• 7891 Real world treatment with molecularly matched targeted therapies in the era of pediatric precision cancer medicine: Gaining ground or inching forward? Jennifer A. Oberg, Jack Boublik-Whiteley
• 7892 Multi-ancestry genome-wide association study (GWAS) of pediatric acute myeloid leukemia (AML) risk identifies four risk loci Cindy Im, Lauren J. Mills, Peggy Meng, Marijana Vujkovic, Jenny N. Poynter, Melissa Maria Hudson, Kirsten K. Ness, Joseph L. Wiemels, Logan G. Spector, Saonli Basu, Zhaoming Wang, Richard Aplenc

在完整检索应用中浏览本分会场 →